Development and Validation of the Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)

Conditions

• Cardiac Dysautonomia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ) — OTHER
  To compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.

Study Details

Main aim will be to compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.

Key Dates

Start date

Jan 31, 2026

Status verified

Nov 2024

Primary completion

Aug 31, 2026

Completion

Aug 31, 2026

Study Design

Enrollment

100 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Arms

• Other: Newly diagnosed/untreated/incompletely treated for Cardiac Dysautonomia Patients
  Newly diagnosed/untreated/incompletely treated for Cardiac Dysautonomia (Postural Orthostatic Tachycardia Syndrome (POTS), Inappropriate Sinus Tachycardia (IST), and Vasovagal syncope (VVS)) Patients
• Other: Previously diagnosed/treated/undergone sinus node modification for Cardiac Dysautonomia Patients
  Previously diagnosed/treated/previously undergone sinus node modification for Cardiac Dysautonomia Patients (Postural Orthostatic Tachycardia Syndrome (POTS), Inappropriate Sinus Tachycardia (IST), and Vasovagal syncope (VVS)) Patients

Primary Outcome Measure

To develop and validate KCDysQ as a quality of life and symptom severity assessment tool [ Time Frame: 3 Months ]

Central Contacts

• Donita Atkins
  816-651-1969
  [email protected]

Locations (3)

Find similar trials in Overland Park, KS